Investment and Collaboration Strategies in Cell and Gene Therapy

This panel, first recorded at the 2022 IO360° Summit addressed:

• What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?
• Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?
• What are investors/pharma partners looking for and how does that inform what people should be doing?
• How do we think about partnerships between organizations?

Moderated by:

Michael Polansky, CEO, Parker Group

Panelists:

• Mark Bonyhadi, PhD, Senior Advisor, Qiming Venture Partners
• Elaine Cheung, SVP, Corporate Strategy & Business Development, Lyell Immunopharma
• Arjun Goyal, MD, MPhil, MBA, Co-founder and Managing Director, Vida Ventures

Learn more about the IO360° Summit at www.io360summit.com